Clinical Trial Update: Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

An early-stage study evaluated an mRNA-transfected dendritic cell vaccine in patients with advanced malignant melanoma. The Phase 1/2 trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• mRNA-transfected dendritic cell vaccine

Snippet

Sponsor: Oslo University Hospital | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED